DA3539 Vascular endothelial growth factor receptor 1 (D1-D5) antigen
see all 46 Vascular endothelial growth factor receptor 1 products
5 µg / US$ 225
NOVUS BIOLOGICALS
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
Quick Overview
Human Vascular endothelial growth factor receptor 1 (D1-D5)
Synonyms
FLT1, FLT, FRT, FLT-1, VEGFR-1, VEGFR1, EC 2.7.10.1, Vascular permeability factor receptor, Tyrosine-protein kinase receptor FLT, Flt-1, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase 1,
Product Description
Human Vascular endothelial growth factor receptor 1 (D1-D5)
Properties
| Presentation | Purified |
| Species | Human |
| Purity | >90% |
| Source | Insect cells |
| Molecular Weight | 70 kD |
| Catalog Number | DA3539 |
| Swiss Prot. No. | P17948 |
| Quantity | 5 µg |
| Price | US$ 225 |
| Delivery | Worldwide |
| Manufacturer | Acris Antibodies GmbH |
| Datasheet | view  DA3539.pdf |
Datasheet Extract
| Background | Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin -like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly, a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.
|
| Immunogen | Swiss Num.: P17948 |
| Source | Insect cells |
| Format | State: Lyophylized, without stabilizer and buffer. Purity: > 90%, by SDS-PAGE and HPLC analyses Endotoxinlevel: < 0.1 ng per mg of VEGFR-1 Reconstitution: The lyophilized product is soluble in water and most aqueous buffers. It should be restored in water to a concentration of 100 ng/ml. |
| Description | Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-5 (sVEGFR-1 D1-5) is a 70 kDa protein. The baculovirus generated, recombinant human sVEGFR-1 is produced as a non-chimeric protein in a monomeric form.
The soluble receptor protein contains only the first 5 extracellular domains, which contain all the information necessary for high affinity ligand binding. Biological Activity: The activity of recombinant human sVEGFR-1 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces. The ED50 for this effect is typically 10 ng/ml. in a 13 day CAM-assay sVEGFR-1 is able to inhibit VEGF stimulated sprouting of capillaries at 30pM. Molecular weight: The receptor monomers have a mass of approximately 70 kDA. |
| Storage | Lyophilised samples are stable for six months at -20°C to -70°C.
Reconstituted sVEGFR-1D1-5 should be stored in working aliquots at -20°C. Avoid repeated freezing and thawing, as this will decrease the activity. Reconstituted material is stable at 2-8°C for two days. |
| References | 1. Röckl et al., Exp Cell Res 241:161-170. |
